Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System
Axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel exhibited increased odds of neurotoxicity, with some discrepancies in their characteristics, profiles, and severity.
Authors
- Jia He (ORCID: https://orcid.org/0000-0002-2338-9501)
- Lei Yuan (ORCID: https://orcid.org/0000-0001-9069-9481)
- Wentao Shi (ORCID: https://orcid.org/0000-0003-2648-1183)
- Xiaofei Ye (ORCID: https://orcid.org/0000-0003-3692-1285)
- Yinghong Zhai (ORCID: https://orcid.org/0000-0001-5872-3568)
- S.-G. Liu
- Yang Cao (ORCID: https://orcid.org/0000-0002-3552-9153)
- Shihua Fang
- Xu Feng (ORCID: https://orcid.org/0000-0003-1091-479X)
- Fangyuan Hu (ORCID: https://orcid.org/0000-0001-5465-7495)
Institutions
- Qinghai University (CN)
- Second Military Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Capital Medical University (CN)
- Örebro University (SE)
- Shanghai Ninth People's Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1080/14740338.2024.2416542
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Shanghai Jiao Tong University